Literature DB >> 33867731

Evaluation of LKB1 and Serine-Glycine Metabolism Pathway Genes (SHMT1 and GLDC) Expression in AML.

Fateme Mezginejad1, Mohammad Hossein Mohammadi1,2, Parinaz Khadem1, Mehdi Allahbakhshian Farsani1,2,3.   

Abstract

LKB1 is a significant tumor suppressor and epigenetic regulator playing a vital role in different types of cancers. SHMT1 and GLDC are two critical genes of the epigenetic pathway influenced by LKB1. As epigenetic is the major cause of AML pathogenesis, this study aimed at investigating LKB1, SHMT1, and GLDC gene expression levels in acute myeloid leukemia patients. The present study was conducted on LKB1, SHMT1, and GLDC gene expression levels in 60 de novo AML samples and 30 normal controls using real-time RT-PCR. The results showed that LKB1 and SHMT1 have respectively a significantly lower (P < 0.05) and higher (P < 0.05) expression level than that of normal controls. Furthermore, the correlation between LKB1 with SHMT1 and GLDC was significant and positive (P value: 0.015, r: 0.299). Positive findings confirm that metabolic pathways alongside the LKB1 association drive the epigenetic axis and its substrate production. Therefore, it can be concluded that the newly-discovered pathway in the pathogenesis of this disease provides new insights into the design of therapeutic targets. © Indian Society of Hematology and Blood Transfusion 2020.

Entities:  

Keywords:  AML; GLDC; LKB1; SHMT1

Year:  2020        PMID: 33867731      PMCID: PMC8012466          DOI: 10.1007/s12288-020-01329-1

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  19 in total

1.  LKB1 loss links serine metabolism to DNA methylation and tumorigenesis.

Authors:  Filippos Kottakis; Brandon N Nicolay; Ahlima Roumane; Rahul Karnik; Hongcang Gu; Julia M Nagle; Myriam Boukhali; Michele C Hayward; Yvonne Y Li; Ting Chen; Marc Liesa; Peter S Hammerman; Kwok Kin Wong; D Neil Hayes; Orian S Shirihai; Nicholas J Dyson; Wilhelm Haas; Alexander Meissner; Nabeel Bardeesy
Journal:  Nature       Date:  2016-10-31       Impact factor: 49.962

2.  Methylation profiling in acute myeloid leukemia.

Authors:  M Toyota; K J Kopecky; M O Toyota; K W Jair; C L Willman; J P Issa
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

3.  Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues.

Authors:  Songmi Noh; Do Hee Kim; Woo Hee Jung; Ja Seung Koo
Journal:  Tumour Biol       Date:  2014-01-05

4.  Clinical significance of SHMT1 rs1979277 polymorphism in Asian solid tumors: evidence from a meta-analysis.

Authors:  T T Zhao; L L Shen; X L Zhang; D Y Gu; Q Zhang; X Y Huo; C J Tang; J F Chen
Journal:  Genet Mol Res       Date:  2015-05-25

Review 5.  Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis.

Authors:  Anna Eriksson; Andreas Lennartsson; Sören Lehmann
Journal:  Exp Hematol       Date:  2015-06-26       Impact factor: 3.084

6.  Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia.

Authors:  Yang Yang; Seisho Takeuchi; Wolf K Hofmann; Takayuki Ikezoe; Jacques J M van Dongen; Tomasz Szczepański; Claus R Bartram; Norihide Yoshino; Hirokuni Taguchi; H Phillip Koeffler
Journal:  Leuk Res       Date:  2005-07-21       Impact factor: 3.156

7.  Evaluation of growth factor independence 1 expression in patients with de novo acute myeloid leukemia.

Authors:  Fatemeh Salarpour; Kourosh Goudarzipour; Mohammad Hossein Mohammadi; Ahmad Ahmadzadeh; Sara Faraahi; Atefeh Allahbakhshian; Mehdi Allahbakhshian Farsani
Journal:  J Cancer Res Ther       Date:  2020 Jan-Mar       Impact factor: 1.805

8.  Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.

Authors:  W Zhang; Y Ding; C Zhang; Q Lu; Z Liu; K Coughlan; I Okon; M-H Zou
Journal:  Oncogene       Date:  2017-03-27       Impact factor: 9.867

Review 9.  Dysregulation of mTOR activity through LKB1 inactivation.

Authors:  Wei Zhou; Adam I Marcus; Paula M Vertino
Journal:  Chin J Cancer       Date:  2013-05-14

Review 10.  Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function.

Authors:  Ren-You Gan; Hua-Bin Li
Journal:  Int J Mol Sci       Date:  2014-09-19       Impact factor: 5.923

View more
  1 in total

Review 1.  Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.

Authors:  Livingstone Fultang; Luciana Gneo; Carmela De Santo; Francis J Mussai
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.